

1 *Review*

2 **Oral dysbiotic communities and their implications in** 3 **systemic diseases**

4 **Preethi Sudhakara**¹, **Abishek Gupta**¹ **Anshumouli Bhardwaj**² and **Aruni Wilson**^{3*}

5 ¹ Department of Genetic Engineering, SRM University, Chennai, India.

6 ² Bharath Biotech International Ltd, Hyderabad, India.

7 ³ Division of Microbiology and Molecular Genetics, School of Medicine, Loma Linda University, CA-92350,
8 USA

9 * Correspondence: aruniwilson@llu.edu; Tel.: +1-909-709-2025

10

11 **Abstract:** The human body supports the growth of a wide array of microbial communities in various
12 niches, such as the oral cavity, gastro-intestinal and urogenital tracts and on the surface of the skin.
13 These host associated microbial communities include yet-un-cultivable bacteria and are influenced
14 by various factors. Together, these communities of bacteria are referred to as the human
15 microbiome. Human oral microbiome consists of both symbionts and pathobionts. Deviation from
16 symbiosis among the bacterial community leads to “dysbiosis” – a state of community disturbance.
17 Dysbiosis occurs due to many confounding factors that predispose to a shift in the composition and
18 relative abundance of microbial communities. Dysbiotic communities have been a major cause for
19 many microbiomes related systemic infections. Such dysbiosis is directed by certain important
20 pathogens called the “keystone pathogens” that could modulate community microbiome variations.
21 One such persistent infection is oral infection, mainly periodontitis, where a wide array of causal
22 organisms has been implied to systemic infections such as cardio vascular disease, diabetes mellitus,
23 rheumatoid arthritis and Alzheimer’s disease. The keystone pathogens co-occur with many yet-
24 cultivable bacteria and their interactions lead to dysbiosis. This has been the focus of recent research.
25 While immune evasion is one of the major modes that lead to dysbiosis, new processes and new
26 virulence factors of bacteria have been shown to be involved in this important process of that
27 determine disease or health state. This review focuses on such dysbiotic communities, their
28 interactions and their virulence factors that predispose the host to other systemic implications.

29 **Keywords:** Oral dysbiosis, Human oral microbiome, yet-un cultivable organisms, systemic diseases.

30 **1. Introduction**

31 Human microbiome plays a pivotal role in human biology through its influence on many
32 physiological functions such as human development, physiology, immunity and nutrition. Even
33 though the composition of the human microbiome has received considerable attention in recent years,
34 the precise mechanisms whereby these microbial communities mediate disease and restore and
35 maintain health remain unexplored. However, recent studies have shown that several chronic
36 diseases of the mouth and gastro-intestinal tract are associated with alterations in the composition of
37 the microbiome termed as “dysbiosis”. Dysbiosis is a significant harmful shift in the relative
38 abundances and individual components of the microbiome which varies with their composition and
39 relative abundances during health status. This shift causes major dysbiosis related diseases in the
40 humans namely, the periodontitis, irritable bowel syndrome, chronic vaginosis etc. Among them,
41 periodontal disease depicts major dysbiotic condition due to their diversity of genera involved in the
42 normal and periodontal microbiome. Oral microbiota consists of two major types of bacteria namely
43 Gram positive and Gram negative bacteria with more than 700 species of microorganisms found in
44 the oral cavity [1].

45 The etiology of periodontitis with both Gram positive and Gram negative bacteria suggest a
46 complex heterogeneous microbial population which could be classified as early and late colonizers

47 [2]. The oral cavity also includes several discrete microbial habitats such as gingival sulcus, teeth,
48 attached gingiva tongue, lip, cheek, hard and soft palate [3]. With a steady transition of various
49 environments such as the oxygen tension and nutrient availability, the bacterial microbiota play a
50 pivotal role in health and disease conditions of which periodontitis is the highly prevalent disease
51 among the world population [4].

52 The periodontal infections are a distinct group of clinical entities which are caused by bacterial
53 communities developing in a complex polymicrobial synergistic association in oral microbiome[1].
54 Approximately 47% of adults in the United States aged between 30 years (approximately 65 million
55 adults) have periodontitis: 30.0% with moderate, 8.5% with severe periodontitis and 8.7% with mild
56 periodontitis. Periodontal infections in addition to heavy monetary healthcare burden also have been
57 linked with many systemic diseases [5]. Periodontitis is a chronic inflammatory disease affecting
58 tissues that surround and support the teeth. Its occurrence is associated with important systemic
59 diseases such as cardiovascular disease [6], rheumatoid arthritis [7], and Alzheimer's disease [8]. One
60 of the most important etiologies of periodontitis is *Porphyromonas gingivalis*, a keystone Gram
61 negative bacterial pathogen [9]. Keystone pathogens can orchestrate inflammatory disease by
62 remodeling a normally benign microbiota, causing imbalance between normal and pathogenic
63 microbiota (dysbiosis) [9-11]. Dysbiosis of oral microbiome in periodontal disease is a hallmark of
64 this condition. Understanding the mechanism of dysbiosis, its functional relevance to disease and
65 strategies to achieve reversal of dysbiosis to restore health has been the prime focus of research.
66 Recent investigations using the mouse model of this disease have demonstrated that the human
67 periodontal bacterium *Porphyromonas gingivalis* acts as a keystone pathogen in manipulating the
68 normal commensal microbiome into a dysbiotic condition even when present at low abundance
69 Furthermore; this dysbiotic microbiome is causative of disease rather than a consequence of the
70 altered environment in this inflammatory condition [10].

71 In this article, the oral dysbiosis caused due to host-microbiome interaction, and the major
72 mechanisms of dysbiosis and bacterial virulence proteins of co-occurring microbiota that predispose
73 the host to systemic disease are briefly reviewed.

74 2. Oral microbiota and microbiome

75 The term "Microbiome" was coined by the Nobel Laureate, Joshua Lederberg. This term was
76 coined to signify the relationship between the micro-organisms and the host such as symbiotic
77 relationship namely commensalism, mutualism and pathogenic. But they are ignored as
78 determinants of health and disease [12]. Oral microbiome otherwise called as oral microflora or oral
79 microbiota is the complex microbial community that resides in the human oral cavity [3].
80 Approximately 500 to 700 species are estimated to be residing in the oral cavity, of which half of them
81 are cultivated anaerobically through microbiological techniques but still half of them remain
82 uncultivable [13]. Oral microbiome is characterized by cultivation-independent molecular methods
83 using 16s RNA gene based cloning studies [13].

84 3. Oral microbiome variations in health and disease

85 The major gateway to human body is the oral cavity. Micro-organisms enter into the human
86 cavity through food and air which passes through nose and then reaches trachea and lungs through
87 mouth [3]. Oral microbiome causes number of oral infectious diseases such as dental caries,
88 periodontitis, endodontic infection, alveolar bone loss and tonsillitis [3]. Studies have proved that an
89 oral infectious disease affects the overall health of an individual, extending beyond the oral cavity
90 such as systemic diseases including obstetric convulsion [14], cardiovascular disease [15],
91 immunological disorder [16], diabetes [17] and respiratory disease [18, 16]. Some of the major
92 systemic implications are dealt with below.

93
94
95

96 3.1. Oral infection in Pre-term birth

97 Pregnancy gingivitis is a term to indicate inflammation which was promoted during pregnancy
98 hormonal changes [19] or caused due to oral consumption of birth control pills [20]. Pre-term birth
99 appears to be a risk factor for the neonatal mortality. *Bacteroides forsythus*, *Porphyromonas gingivalis*,
100 *Agregatibacter actinomycetemcomitans*, *Treponema denticola*, *Fusobacterium nucleatum*, *Campylobacter*
101 *rectus*, *Peptostreptococcus micros*, *Prevotella nigrescens* and *Prevotella intermedia* are the oral microbiome
102 that are detected in high levels in the mothers of pre-term birth infants [21, 22]. The oral infection
103 could mediate the pre-term birth and low birth weight in infants through one or more of the following
104 mechanism such as, (1) Translocation of oral microbiomes to the fetoplacental unit through inducing
105 fetal or maternal response that result in the pre-term birth [23, 24]. (2) Systemic dissemination of
106 prostaglandins and inflammatory mediators such as IL-6 (Interleukin - 6), IL-8 (Interleukin - 8), TNF
107 - α (Tumor necrosis factor alpha) and PGE2 (Prostaglandin E2) on the fetal placental unit [24].
108 (3) Action of oral microbiomes reservoir of Lipopolysaccharides on the fetal placental unit [24].
109

110 Though there are sufficient evidences to prove that periodontal infection remains as a significant
111 cause for the pre-term birth in infants it remains conflicting. However, oral hygiene during pregnancy
112 is one of the preventive measures.

113 3.2. Oral infection and diabetes

114 Diabetes Mellitus (DM) is a clinical syndrome that is characterized by hyperglycemia which is
115 caused due to deficiency of insulin. It affects all age groups. Type 2 diabetes mellitus substantially
116 increases the risk of periodontal disease and has been proposed to modulate oral microbial
117 communities. A shift to a more pathogenic bacterial profile may explain the greater risk of
118 periodontal disease in diabetic patients. Animal studies provide support for such a shift as a
119 mechanism for the increased risk of periodontitis in diabetes mellitus [25]. Studies have also shown
120 that type 2 diabetes may alter subgingival bacterial community through changes in substrate
121 availability driven by inflammation and glucose availability [26]. This could be driven by substrate-
122 related alterations in the gingival sulcus in DM that may provide a microenvironment conducive to
123 bacterial growth [27-30]. Consistent with this, a number of studies have shown that DM alters the
124 colonization of various tissues by pathogenic bacteria. *Helicobacter pylori* infection [31], bacterial
125 infection of foot ulcers, susceptibility to tuberculosis infection and colonization of the urinary tract
126 by pathogenic bacteria are all significantly enhanced in diabetic individuals [32]. That DM enhances
127 susceptibility to infection by pathogenic bacteria in many different target organs, this could be due
128 to changes in bacterial substrate availability including sugars and inflammatory products that
129 support bacterial growth. Though the link between oral infection and diabetes mellitus is not yet
130 fully recognized and understood by medical community, there are many theories such as chronic
131 hyperglycemia and increased secretion of prostaglandin E₂ and Tumor necrosis factor alpha (TNF- α)
132 are caused by the advanced glycation end products accumulation and presence of oral microbiome
133 in the tissue due to impairment of polymorphonuclear leukocyte function [33, 34] and change in
134 collagen metabolism due to increase in collagenase activity and decrease in collagen synthesis [35].

135 Many further studies are currently underway to determine the relationship between oral
136 infection and diabetes in detail.

137 3.3. Oral infection and cardiovascular diseases

138 Cardiovascular disease (CVD) is a chronic disease that involves blood vessels or heart.
139 Cardiovascular disease includes myocardial infarction, atherosclerosis, stroke and congestive heart
140 failure due to genetic as well as environmental factors [36]. Apart from the above factors, oral
141 microbiome infection also plays a significant role in triggering the cardiovascular disease. Among the
142 periodontal bacteria, *Streptococcus sanguinis* and *Porphyromonas gingivalis* are commonly involved in
143 cardiovascular disease [37].

144 The systemic inflammation of blood vessel wall in the presence of molecular mimicry and
145 inflammatory mediator and inflammation by direct oral microbiome action such as direct invasion
146 of bacteria to pocket wall and phagocyte-mediated bacterial translocation are the two modes by
147 which the oral microbiome invades the vascular tissue forming acute inflammation, further forming
148 resolution and homeostasis leading to chronic inflammation which causes cardiovascular disease
149 [38].

150 4. Periodontitis and associated bacteria

151 Periodontal disease is one of the major ubiquitous diseases of the oral microbiome that causes
152 tooth loss in adults [39]. The oral diseases are a disparate group of clinical entities where
153 inflammation results in loss of attachment between the teeth and gingivae with the formation of
154 periodontal pockets, which later leads to tooth loss contributing to tissue affliction [39, 40].

155 There are two main categories of periodontal disease where the tooth loses its endorsing
156 structures are: aggressive periodontitis and chronic periodontitis. These diseases can be characterized
157 beyond the extent of bone loss as generalized or localized and the austere of the disease as slight,
158 moderate, or advanced [41]. Most of them suffer from chronic periodontitis, an insidious disease
159 where the annihilation is consistent with the presence of bacterial plaque and mineralized plaque or
160 calculus [42]. Chronic periodontitis is caused by the variable microbial patterns with polymicrobial
161 infection. In deviance, aggressive periodontitis comprises of rapid attachment loss and bone
162 destruction [43]. Localized form of aggressive periodontitis is an unusually unique disease relative
163 to other forms of periodontitis which usually occurs during adolescence who usually shows a low
164 incidence of periodontal disease; bone resorption in aggressive periodontitis progresses faster than
165 that of observed in chronic periodontitis [44], may spontaneously arrest [45], and is localized to
166 distinctive teeth (first molars and incisors); ensuing, the infection tends to aggregate together
167 indicating susceptibility to the disease may be genetically regulated [46, 47].

168 Periodontal diseases commence with the aggregation of primary colonizers, usually facultative
169 anaerobes and Gram-positive aerobes such as streptococci, onto the tooth surfaces. This colonization
170 is succeeded by the additional aggregation of late colonizers, which are usually Gram-negative
171 members of the “red complex”, namely *T.denticola*, *T.forsythia*, and *P. gingivalis* in addition to other
172 Gram-negative organisms [48]. The broadly known periodontal pathogens present in plaque are
173 *Porphyromonas gingivalis*, *Treponema denticola*, *Prevotella intermedia*, *Campylobacter rectus*, *Tannerella*
174 *forsythia*, *Agregatibacter actinomycetemcomitans*, *Selenomonas spp.*, *Fusobacterium nucleatum*, *Parvimonas*
175 *micra* and *Eubacterium timidum* [49]. Recent microbiome studies have disclosed emerging new
176 pathogens as *Filifactor alocis*, which may play significant role in periodontal diseases [50]. There are
177 increasing evidence to suggest that *F. alocis* plays an important role in community dynamics thereby
178 could be a major player causing dysbiosis. The unique synergism between *P. gingivalis* and *F. alocis*
179 were also noted in our earlier study [63].

180 5. Yet- un-cultivable bacteria and the recent shift in oral dysbiosis research

181 Recent studies conducted on oral microbiome over the last few years have altered our level of
182 understanding the polymicrobial communities and their association to health and disease. Their
183 increase in diversity of microbes and its composition gives an idea for identification and cultivation
184 of more taxon than recognized previously. Some other bacterial species, such as *Aggregatibacter*
185 *actinomycetemcomitans*, *Prevotella intermedia*, *Selenomonas noxia*, *Eubacterium nodatum* and
186 *Fusobacterium nucleatum* are found to be correlated with periodontitis, along with the red-complex
187 pathogens [51]. In addition, micro-organisms such as *Desulfobulbus*, *Synergistes*, *Selenomonas*, TM7
188 (new candidate bacterial division) and *Filifactor alocis* have been identified as potential pathogens [3].
189 Furthermore, 20% to 60% of the species identified in the oral cavity are yet to be cultivated [3, 52].

190 Recent theories on the etiology of periodontitis show a decrement in benign symbioses and an
191 increase in micro-organisms with ameliorated pathogenic potential, favors a paradigm shift in
192 microbial composition [53]. Hence, increment in oral microbiome diversity and its composition leads
193 to conclude that pathogenic communities contain high levels of fastidious and yet-un-cultivated

194 bacteria than previously recognized [3]. Among them, *Filifactor alocis* [54, 55] is an emerging pathogen
195 that is present in significantly high numbers in adult periodontitis, refractory periodontitis,
196 endodontic infections [56-58] and in aggressive periodontitis [59]. This bacterium has been identified
197 as potential pathogen in a number of independent studies [3, 52, 60-62]. Aruni et al, [63] and Wang
198 et al., [64] have described several of its potential virulence attributes, of *F. alocis*. Moreover, Chen et.
199 al., [65] recently reported that *F. alocis* was invariably present across various oral habitats in those
200 with periodontitis. *F. alocis* both co-occurred with other pathogens and appeared to play a central role
201 in organizing these pathogens.

202 5.1. *Filifactor alocis*

203 *F. alocis* is a Gram-positive, asaccharolytic, obligate anaerobic rod. Considered one of the marker
204 organisms and an important periodontal pathogen. The organism is now identified to be significant
205 to the pathogenic structure of biofilms associated with periodontal inflammation [43, 61, 62]. In
206 comparison with the other traditional periodontal pathogens, the high incidence of *F. alocis* in the
207 periodontal pocket compared with its absence in healthy individuals or those who are periodontitis-
208 resistant has highlighted its importance in the infectious disease process [61, 62, 66]. This organism
209 *F. alocis*, while heterogeneous, has virulence properties that may enhance its ability to survive and
210 persist in the periodontal pocket [63]. Its relative resistance to oxidative stress and stimulated growth
211 under those conditions are considered to be important attribute [63]. Furthermore, *F. alocis* has been
212 shown to induce secretion of pro-inflammatory cytokines, triggering apoptosis of gingival epithelial
213 cells [67]. Additionally, colonization and survival of *F. alocis* in a mouse model showed pro-apoptotic
214 local infection that is rapidly resolved by host neutrophil influx [64]. Moreover, in co-culture with *P.*
215 *gingivalis*, *F. alocis* showed an increased invasive capacity of *HeLa* cells [63]. Analysis of emerging
216 research shows that *F. alocis* is a marker organism for periodontitis. It has unique characteristics that
217 may enhance its virulence potential [18, 43, 53, 56, 63, 64, 67-71]. *F. alocis* could be one of the organisms
218 that can play a pivotal role in community dynamics, establishing synergistic partnerships with other
219 pathogenic oral bacteria during the disease state. In comparison with other Gram-positive bacteria of
220 the oral cavity, the variations induced in the host proteome during *F. alocis* synergism could lead to
221 many systemic host responses. Therefore, the significance of *F. alocis* putative virulence factors, which
222 may trigger the key host response, deserves further intensive study. It is noteworthy that *F. alocis* is
223 one of only a few organisms associated with both generalized and localized aggressive periodontitis
224 (LAP) in addition to peri-implantitis and endodontic infections. Hence, *F. alocis* is considered an
225 important species of the pathogenic oral microbiome.

226 6. Oral dysbiosis

227 Some diseases are caused due to change in the relationship of microbiome and the host; decrease
228 in the beneficial symbionts wherein increasing the pathogenic potential causing microbiome
229 imbalance inside the human body. This process is known as dysbiosis [72]. Oral dysbiosis is the
230 gateway to periodontitis and its associated diseases.

231 7. Causes of Oral dysbiosis

232 Oral hygiene is the first and the foremost cause for dysbiosis of oral microbiome. Other major
233 factors causing oral dysbiosis include poor oral hygiene, dietary habits, smoking, gingival
234 inflammation, genetic difference and dysfunction of salivary glands such as activity of salivary
235 proteins [73-75]. A dysbiotic shift and the microbiome imbalance in the oral cavity lead to formation
236 of biofilm microbial community [76]. According to recent concept evident through earlier studies, it
237 is known that in healthy host, the pathogens are found very few in numbers at the healthy sites and
238 hence, the oral diseases are caused due to oral microbiome variations rather than exogenous infection
239 [77]. Whereas in dysbiosis, the pathogenic bacteria grows remarkably high with anodyne
240 components in biofilm surface [77]. This alteration in the formation of biofilm in the oral cavity results

241 in accumulation of large proportion of microbes as dental plaque biofilm [78]. Oral dysbiosis not only
 242 causes oral related diseases but also systemic diseases due to manipulation of host response.

243

244 The subgingival environment is rich in immune and inflammatory mediators and provides
 245 unique challenges and opportunities for the bacteria [79-81]. Periodontal health requires a controlled
 246 immuno-inflammatory state that can maintain host-microbe homeostasis in the periodontium [82].
 247 However, in periodontitis, the host immune response is dysregulated either because it is subverted
 248 by the microbial community or because of host immunoregulatory defects and is therefore ineffective
 249 to restrain bacterial outgrowth and overt pathogenicity [11]. A poorly controlled host immune
 250 response, in turn, can generate a self-perpetuating pathogenic cycle where dysbiosis and
 251 inflammation reinforce each other. Among the immune cells, neutrophils represent the primary
 252 cellular defense in healthy oral tissues. They are the most common leukocytes recruited to the
 253 periodontal pocket and are indispensable for periodontal tissue homeostasis. Neutrophils are not
 254 adept at phagocytosing biofilm-associated bacteria, which eventually leads to 'frustrated
 255 phagocytosis' [83]. During this process, neutrophil-derived toxic substances may also be released to
 256 the underlying tissue, causing collateral damage to tooth-supportive tissues, as they function as
 257 double edged swords hence, a collateral damage can be exerted by hyperactive neutrophils or
 258 neutrophils in excessive numbers. Many bacteria especially *P. gingivalis* can subvert neutrophil
 259 functions and related immune responses causing dysbiotic community through impaired immune
 260 response. However, the role of its close synergistic bacterial counterparts (such as *F. alocis*) are yet to
 261 be studied in detail.

262 Specific molecular mechanisms by which periodontal bacteria manipulate the host response to
 263 cause dysbiotic inflammation are elaborately described in other reviews [83, 84].

264

265 **Table 1.** Table showing various mechanisms of immune subversion and their outcome [84].

266

Mechanisms	Outcome
Whole cells, LPS bind to adhesion molecules (IL-8, ICAM-1, E-selectin).	Impaired recruitment
SerB suppression of IL-8 production by dephosphorylation of the Ser536 of NF-kB p65 preventing nuclear translocation and transcription.	IL-8 production suppressed
Bacterial binding to FMLP and PPAD-citrullinated C5a.	Reduced chemotaxis
Dual regulation of TREM-1 by Arg- and Lys-gingipain. Outcome depends on infection stage.	Evasion of host defense
Resistance to killing by granular contents. C5 convertase-like activity produces C5a, which is involved in subversion of C5aR TLR2 crosstalk. This leads to My88D degradation, PI3K activation and inhibition of RhoA GTPase.	Killing prevented. Inhibits antimicrobial response and promotes inflammatory response
Activated CR3 interacts with <i>P. gingivalis</i> fimbriae and induces downregulation of IL-12p70 a key cytokine in intracellular bacterial clearance.	Reduced bacterial clearance
LPS and lipid A delay neutrophil apoptosis through TLR2 signalling	Prolonged acute inflammation

267

268 Recently studies from our lab has shown that the glycan modification due to oral bacterial
 269 sialoglycosidases (family of sialic acid modifying enzymes) could play a vital role in maturation of
 270 major virulence factors such as the gingipains and LPS. This in turn could play a role in sialic acid

271 binding ligands in neutrophils leading to neutrophil immune subversion causing dysbiosis (Aruni
272 Wilson personal communication).

273 8. Oral bacterial proteins involved in dysbiosis

274 Certain periodontal pathogens express major virulence proteins that impact apoptotic cell death
275 in gingival epithelial cells (GEC) by disrupting cytokine networks. For example, it has been identified
276 that major virulence proteins *F. alocis* and *P. gingivalis* modulate epithelial cells on co-infection and
277 are responsible for host cell signaling, metabolic host response, cell-cell interaction, regulation of
278 oncogenes in the oral microbiomes [18].

279 The up regulation of osteoclast pathway stimulation, increase in alveolar bone resorption and
280 also tissue degradation through metalloproteinase and inflammatory mediators are induced through
281 secretion of several cytokines by oral microbiome leading to disrupted cytokine homeostasis and
282 finally tissue degradation [67]. Caspase-3 utilizing extrinsic pathway induce apoptosis and suppress
283 MEK1/2 expression which may lead to apoptotic induction [85].

284 Apoptosis are triggered by secretion of certain proinflammatory cytokines, including tumor
285 necrosis factor alpha (TNF- α), interleukin-1 β (IL-1 β) and IL-6 which are induced from gingival
286 epithelial cells [67].

287 Several proteins namely, microbial surface component-recognizing adhesion matrix molecules
288 (MSCRAMMs) contribute significantly in Gram-positive bacterial virulence by mediating precocious
289 steps in clinical infection such as adhesion and colonization of host tissues [18]. Since host-pathogen
290 interaction may support growth and modulation of metabolic processes the role of amino acid
291 metabolism especially the arginine most prevalent in the periodontal niche may be responsible for
292 the overall pathogenicity.

293 Proteome analysis plays a key role in understanding the process of dysbiotic inflammation
294 through a better understanding of the related molecular mechanisms such as adhesion, invasion,
295 pathogenesis, survival and adaptation in several oral pathogens such as *Streptococcus oralis* [86],
296 *Streptococcus mutants* [87], *P. gingivalis* [88] and *Fusobacterium nucleatum* [89].

297 Proteome analysis of *F. alocis* showed several proteases such as CaaX proteases, metal dependent
298 proteases, calcium dependent proteases and sialoglycoproteases
299 (<http://www.ncbi.nlm.nih.gov/genomeprj/46625>). Expression of these proteases was found to be
300 elevated in co-culture with *P. gingivalis*. Proteins such as Acetyl glutamate kinase, Ornithine
301 transaminase, Aminotransferase and Glutamate racemase were identified to be involved in ornithine
302 biosynthesis. Several proteins contributing to virulence potential of *F. alocis* were identified such as
303 leucotoxin translocation ATP-binding protein, CBARP (Voltage dependent calcium channel beta
304 subunit-associated regulatory protein), fibronectin-binding protein, fimbrial assembly protein, Type
305 IV pilus assembly protein, toxin-antitoxin component protein, Hemolysin III type calcium-binding
306 protein and NAPA (Neutrophil Activating Protein A) [68].

307 *F. alocis* proteome contain proteins involved in ornithine biosynthesis and catabolism, urea
308 breakdown such as arginine deiminase, ornithine transaminase, acetyl glutamate kinase, glutamate
309 racemase, amidotransferase, arginine-tRNA ligase, aminotransferase, arginine decarboxylase [68]. *F.*
310 *alocis* OTC (Ornithine transcarbamylase) has also shown to be involved in the citrullination of
311 proteins via the ADI (Arginine Deiminase) pathway. Since protein catabolism is an alternative
312 source of energy in asaccarolytic oral bacteria, heavy amounts of ammonia production occur in
313 periodontal pockets leading to oral dysbiosis [68].

314 Novel proteins of *P. gingivalis* namely the sialoglycosidases that interact with sialic acid of the
315 host cells have been recently considered to play an important role in facilitating dysbiosis [90]. In the
316 saliva rich environment the mucus containing glycans are considered a vital source as energy for
317 bacterial growth and survival. Manipulation of the sialic acid is recently considered a mechanism to
318 trigger immune evasion through prevention of sialic acid – siglec (Sialic acid binding lectins)
319 interactions in neutrophils.

320 Major proteins involved in citrullination have been identified to cause post translational
321 modifications in the host predisposing to rheumatoid arthritis. One of our study has identified

322 arginine deaminase of *F. alocis* to be involved in a process similar to the peptidyl arginine deiminase
323 of *P. gingivalis* causing peptidyl citrullination [69].

324 9. Proteins of oral bacteria related to systemic diseases

325 Apart from the proteins of oral microbiome that causes oral related disease, there are several
326 other oral bacteria proteins that cause systemic diseases. Proinflammatory mediators such as IL-1 β
327 (Interleukin- 1 β), TNF- α (Tumor necrosis factor – α) and PGE2 (Prostaglandin E2) are released in
328 high levels that exaggerate the host response to the microbes that causes systemic infection in the
329 humans [91, 92]. In case of preterm birth, an elevated levels of cytokine IL-6 has been identified in
330 the host along with IL-1 β , TNF- α and PGE2, that causes the infection in the amniotic fluid which
331 leads to complication in the delivery [93].

332 Studies shows that, a protease namely Gingipain R released from *P. gingivalis* in large quantities
333 causes cardiovascular disease by activating factor X, prothrombin and protein C, thus thrombotic
334 tendency is promoted as thrombin is released, aggregation of subsequent platelets, transformation of
335 fibrinogen to fibrin and intravascular clot formation [21]. Also, recent studies indicate that chronic
336 oral infection induces high proportion of Hsp65 (Heat Shock Protein) that increases cardiovascular
337 risks [94, 95].

338 Many oral microbiome proteins related to systemic diseases still remain as hypothetical proteins.
339 Their functions need to be determined.

340 10. Stem cell modulation by oral pathobionts

341 One of the major effects of pathogenic oral microbiome is manifested in the oral stem cell
342 modulatory processes. Our preliminary study showed secretory proteins of *P. gingivalis* modulated
343 stem cell characteristics. Stem cells contribute to host defense and inflammation. During bacterial -
344 inflammatory disease, stem cells are subjected towards the site of damage, hence come close to
345 bacteria and its components. Previous studies using epithelial cells infected by bacteria have showed
346 modulation of various important functional pathways and changes in gene regulation [63].
347 Extracellular bacterial proteins secreted in a chronic bacterial infection could modulate stem cells and
348 affect tissue regeneration. Our studies using transcriptomic approach employing induced pluripotent
349 stem cell iPSCs (Induced Pluripotent Stem Cells) were used to evaluate the phenotypic and molecular
350 characteristics. The iPSCs were incubated in different experimental conditions with the secreted
351 proteins of pathogenic bacteria - *Porphyromonas gingivalis*, a commensal bacterium - *Enterococcus*
352 *faecalis* and a beneficial bacterium - *Lactobacillus casei* to comparatively evaluate the expression of key
353 genes that govern stemness and differentiation. Secretory proteins of pathogenic bacteria - *P.*
354 *gingivalis*, were found to possess a modulatory effect both on the stemness and the differentiation of
355 stem cells. It is likely that during a chronic bacterial infection, this could prolong stemness and
356 prevent differentiation. Hence, sustain infectious state and prevent cell recovery.

357 11. Animal models for studying systemic diseases caused due to periodontitis

358 Experimentally induced animal models are critically important which is used to study and
359 analysis different aspects of the oral disease and also the systemic diseases caused due to oral
360 dysbiosis. Though human cell culture or *in-vitro* cell culture were found to be useful models, the
361 findings about the host-microbe interaction was anonymous and obscure and hence the animal model
362 (*in-vivo*) came into limelight [96]. A detailed review on this topic can be found in [96].

363 Nonhuman Primates have similar oral structures as that of humans. In particular, rhesus
364 monkey (*Macaca mulatta*), cynomolgus monkeys (*Macaca fascicularis*) and baboons (*Papioanubis*) are
365 susceptible to disease. They are inoculated with human pathogens and then tested. But, they are
366 prone to tuberculosis which makes them less practical model [97].

367 Minnesota Miniature Pigs have maxillofacial and oral structures analogous to those of humans
368 in terms of physiology, anatomy and progression of disease [98]. However, miniatures pigs are
369 relatively expensive and only very few studies are available to support their use [96].

370 The host-microbiome interactions in the rodent model are similar to the human. Rats are often
371 used as an effective model. They are inexpensive and obtained easily with different microbial status.
372 Sometimes swamp rice rats (*Oryzomys palustris*) are widely used to assess some therapeutic models
373 and the dietary effects [96, 98].

374 Baker mouse model, chemically induced model and murine back abscess model are used to
375 examine the alveolar bone resorption, inflammatory response and the interaction of host response
376 and oral microbiome to various phylotypes that leads to systemic disease [99] respectively. But, since
377 they are small in size, they are needed in large quantities.

378 Rabbits, Ferrets and Hamsters are also used as animal models. Each of the animal models has its
379 own advantage and disadvantage, though most of them show similarities to human disease. Among
380 these, mice and rats models are useful for understanding certain aspects of host-microbiome
381 interaction and their therapies. They are being successfully used to study the “dysiosis-rebiosis”
382 concept of oral health restoration.

383 Though the animal models provide a huge number of findings and data, it is occasionally
384 arduous to ascertain whether the findings and data are pertinent to human [96].

385 12. Conclusion

386 Recent studies pave a paradigm shift in emphasizing oral ecosystem to be vital to maintaining
387 oral and overall health of the body. Maintaining microbial equilibrium within oral cavity protect
388 pathogens from manifesting disease state. Disturbing homeostasis of the oral cavity can flare
389 pathogen activity leading to disease state. Because oral cavity being the primary gateway to body
390 may result in spreading infection to other body sites producing systemic diseases. What is known
391 until now is all about oral bacterial species that can be cultivated and sequenced and that can be
392 obtained from pure culture approaches. However, this does not reflect their actual behavior in
393 complex microbial communities. Because, the species that have been identified by culture
394 independent methods are still classified as uncultivated phylotypes. Their impact on community
395 dynamics and their role in oral dysbiosis is yet to be fully explored. Furthermore, newer concepts to
396 study dysbiosis through immune subversion mechanisms involving glycan mediated pathogen-host
397 interactions is currently being explored. Recent research focus on bacteria such as *F. alocis* and other
398 new candidates are gaining momentum. Their collective role in community dynamics is yet to be
399 clearly explored. Hence, an insight into community level physiological and metabolic capacity will
400 help find new cure to modulate activity of such communities and steer them forwards health state.
401 Their synergistic and competitive contributions to oral dysbiosis could reveal new insight into
402 specific species, or its genes or pathways of interest to develop novel therapeutics. Analysis of human
403 oral microbiome will significantly contribute to the development of precise medical interventions.

404 **Acknowledgment:** This work was supported by Loma Linda University and Public Health Service Grant R03-
405 DE026526 from the National Institute of Dental and Craniofacial Research (NIDCR) (to A.W). The authors also
406 wish to acknowledge Dr. Hansel Fletcher, Professor and Vice Chair, Division of Microbiology and Mol. Genetics,
407 LLU. Due to the Journal’s editorial limitations, we apologize to our colleagues/ fellow scientists for not including
408 their references in the review. The authors declare no potential conflicts of interest with respect to the authorship
409 and/or publication of this article.

410 **Author Contributions:** PS - worked on the major contribution, typing, correction and revisions of the
411 manuscript, AG,AB- section contribution, AW- overall manuscript revision.

412 **Conflicts of Interest:** “The authors declare no conflict of interest.”

413 References

- 414 1. Belstrom, D.; Fiehn, N.E.; Nielsen, C.H.; Kirkby, N.; Twetman, S.; Klepac-Ceraj, V.; Paster, B.J. and
415 Holmstrup, P. Differences in bacterial saliva profile between periodontitis patients and a control cohort. *J*
416 *Clin Periodontol.* **2014**, *41*, 104-12, DOI: 10.1111/jcpe.12190.
- 417 2. Kolenbrander, P.E.; Andersen, R.N.; Blehert, D.S.; Eglund, P.G.; Foster, J.S. and Palmer, R.J. Jr.
418 Communications among oral bacteria. *Microbiol Mol Biol Rev.* **2002**, *66*(3), 486–505.

- 419 3. Dewhirst, F.E.; Chen T.; Izard J.; Paster, B.J.; Tanner, A.C.R.; Yu, W.H.; Lakshmanan, A. and Wade W.G.
420 The Human Oral Microbiome. *J Bacteriol.* **2010**, *192*, 5002-5017, DOI:10.1128/JB.00542-10.
- 421 4. Thornton-Evans, G.; Eke, P.; Wei, L.; Palmer, A.; Moeti, R.; Hutchins, S. and Borrell, L.N. Periodontitis
422 among adults aged ≥ 30 years - United States, 2009-2010. *MMWR Surveill Summ.* **2013**, *62(Suppl 3)*, 129-
423 135.
- 424 5. Meyer, P.A.; Yoon, P.W. and Kaufmann, R.B. Introduction: CDC Health Disparities and Inequalities Report
425 - United States, 2013. *MMWR. Surveill. Summ.* **2013**, *62 Suppl 3*, 3-5.
- 426 6. Genco, R.J. and Van Dyke, T.E. Prevention: Reducing the risk of CVD in patients with periodontitis. *Nat*
427 *Rev Cardiol.* **2010**, *7(9)*, 479-80, DOI: 10.1038/nrcardio.2010.120.
- 428 7. Bingham, C.O. and Moni, M. Periodontal disease and rheumatoid arthritis: the evidence accumulates for
429 complex pathobiologic interactions. *Curr Opin Rheumatol.* **2013**, *25(3)*, 345-53, DOI:
430 10.1097/BOR.0b013e32835fb8ec.
- 431 8. Poole, S.; Singhrao, S.K.; Kesavalu, L.; Curtis, M.A. and Crean, S. Determining the presence of
432 periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. *J Alzheimers*
433 *Dis.* **2013**, *36(4)*, 665-77, DOI: 10.3233/JAD-121918.
- 434 9. Darveau, R.P.; Hajishengallis, G. and Curtis, M.A. *Porphyromonas gingivalis* as a Potential Community
435 Activist for Disease. *J Dent Res.* **2012**, *91(9)*, 816-20, DOI: 10.1177/0022034512453589.
- 436 10. Hajishengallis, G.; Liang, S.; Payne, M.A.; Hashim, A.; Jotwani, R.; Eskan, M.A.; McIntosh, M.L.; Alsam, A.;
437 Kirkwood, K.L.; Lambris, J.D.; Darveau, R.P. and Curtis, M.A. Low-Abundance Biofilm Species
438 Orchestrates Inflammatory Periodontal Disease through the Commensal Microbiota and Complement. *Cell*
439 *Host Microbe.* **2011**, *10(5)*, 497-506, DOI: 10.1016/j.chom.2011.10.006.
- 440 11. Hajishengallis, G. and Lamont, R.J. Beyond the red complex and into more complexity: the polymicrobial
441 synergy and dysbiosis (PSD) model of periodontal disease etiology. *Molecular oral microbiology* **2012**, *27(6)*,
442 409-419, DOI:10.1111/j.2041-1014.2012.00663.x.
- 443 12. Lederberg, J. and McCray, A.T. 'Ome sweet 'omics—a genealogical treasury of words. *Scientist.* **2001**, *15*,
444 8-10.
- 445 13. Jumas-Bilak, E.; Carlier, J.P.; Jean-Pierre, H.; Citron, D.; Bernard, K.; Damay, A.; Gay, B.; Teyssier, C.;
446 Campos, J. and Marchandin, H. *Jonquetella anthropi* gen. nov., sp. nov., the first member of the candidate
447 phylum 'Synergistetes' isolated from man. *Int. J. Syst. Evol. Microbiol.* **2007**, *57*, 2743-2748.
- 448 14. Offenbacher, S.; Jared, H.L.; O'Reilly, P.G.; Wells, S.R.; Salvi, G.E.; Lawrence, H.P.; Socransky, S.S. and Beck,
449 J.D. Potential pathogenic mechanisms of periodontitis associated pregnancy complications. *Ann.*
450 *Periodontol.* **1998**, *3*, 233-250.
- 451 15. Beck, J. D. and Offenbacher, S. Systemic effects of periodontitis: epidemiology of periodontal disease and
452 cardiovascular disease. *J. Periodontol.* **2005**, *76*, 2089-2100, DOI: 10.1902/jop.2005.76.11-S.2089.
- 453 16. Beck, J.D.; Slade, G. and Offenbacher, S. Oral disease, cardiovascular disease and systemic inflammation.
454 *Periodontol.* **2000**, *23*, 110-120.
- 455 17. Genco, R.J.; Grossi, S.G.; Ho, A.; Nishimura, F. and Murayama, Y. A proposed model linking inflammation
456 to obesity, diabetes, and periodontal infections. *J. Periodontol.* **2005**, *76*, 2075-2084, DOI:
457 10.1902/jop.2005.76.11-S.2075.
- 458 18. Aruni, A.W.; Zhang, K.; Dou, Y. and Fletcher, H.M. Proteome Analysis of Coinfection of Epithelial Cells
459 with *Filifactor alocis* and *Porphyromonas gingivalis* shows modulation of Pathogen and Host Regulatory
460 Pathways. *Infection and Immunity.* **2014**, *82*, 3261-3274.
- 461 19. Loe, H., and Silness, J. Periodontal disease in pregnancy: prevalence and severity. *Acta Odontol. Scand.* **1963**,
462 *21*, 532-551.
- 463 20. Kalkwarf, K.L. Effect of oral contraceptive therapy on gingival inflammation in humans. *J. Periodontol.* **1978**,
464 *49*, 560-563.
- 465 21. Li, X.; Kolltveit, K.M.; Tronstad, L. and Olsen, I. Systemic Diseases Caused by Oral Infection. *Clinical*
466 *Microbiology Reviews.* **2000**, *13(4)*, 547-558.
- 467 22. Davenport, E.S. Preterm low birthweight and the role of oral bacteria. *Journal of Oral Microbiology* **2010**, *2*,
468 5779, DOI:10.3402/jom.v2i0.5779.
- 469 23. Byrne, J.; Ellsworth, C.; Bowering, E. and Vincer, M. Language development in low birth weight infants:
470 the first two years of life. *J. Dev. Behav. Pediatr.* 1993, *14*, 21-27.
- 471 24. McGaw, T. Periodontal diseases and pre-term delivery of low birth weight infants. *J Can Dent Assoc.* **2002**,
472 *68*, 165-9.

- 473 25. Graves, D.T.; Liu, R.; Alikhani, M.; Al-Mashat, H. and Trackman, P.C. Diabetes-enhanced inflammation
474 and apoptosis--impact on periodontal pathology. *J Dent Res.* **2006**, *85*(1), 15-21, DOI:
475 10.1177/154405910608500103
- 476 26. Salvi, G.E.; Kandykaki, M.; Troendle, A.; Persson, G.R. and Lang, N.P. Experimental gingivitis in type 1
477 diabetics: a controlled clinical and microbiological study. *J Clin Periodontol.* **2005**, *32*(3), 310-316.
- 478 27. Ardakani, M.R.; Moeintaghavi, A.; Haerian, A.; Ardakani, M.A. and Hashemzadeh, M. Correlation
479 between levels of sulcular and capillary blood glucose. *J Contemp Dent Pract.* **2009**, *10*, 10-17.
- 480 28. Sakallioğlu, E.E.; Lutfioğlu, M.; Sakallioğlu, U.; Diraman, E. and Keskiner, I. Fluid dynamics of gingiva in
481 diabetic and systemically healthy periodontitis patients. *Arch Oral Biol* **2008**, *53*, 646-651.
- 482 29. Salvi, G.E.; Franco, L.M.; Braun, T.M.; Lee, A.; Persson, G.R.; Lang, N.P. and Giannobile, W.V. Pro-
483 inflammatory biomarkers during experimental gingivitis in patients with type 1 diabetes mellitus: a proof-
484 of-concept study. *J Clin Periodontol.* **2010**, *37*, 9-16.
- 485 30. Engebretson, S.; Chertog, R.; Nichols, A.; Hey-Hadavi, J.; Celenti, R. and Grbic, J. Plasma levels of tumour
486 necrosis factor-alpha in patients with chronic periodontitis and type 2 diabetes. *J Clin Periodontol.* **2007**, *34*,
487 18-24.
- 488 31. Ojetti, V.; Pellicano, R.; Fagoonee, S.; Migneco, A.; Berrutti, M. and Gasbarrini, A. *Helicobacter pylori*
489 infection and diabetes. *Minerva Med.* **2010**, *101*, 115-119
- 490 32. Chen, S.L.; Jackson, S.L. and Boyko, E.J. Diabetes mellitus and urinary tract infection: epidemiology,
491 pathogenesis and proposed studies in animal models. *J Urol.* **2009**, *182*, S51-56.
- 492 33. Ritchie, C.S. Mechanistic links between type 2 diabetes and periodontitis. *J Dent* **2009**, *37*, 578-9.
- 493 34. Moore, P.A.; Weyant, R.J.; Mongelluzzo, M.B.; Myers, D.E.; Rossie, K.; Guggenheimer, J.; Block, H.M.;
494 Huber, H.; Orchard, T. Type 1 diabetes mellitus and oral health: Assessment of periodontal disease. *J*
495 *Periodontol* **1999**, *70*, 409-17, DOI: 10.1902/jop.1999.70.4.409.
- 496 35. Al-Maskari, A.Y.; Al-Maskari, M.Y. and Al-Sudairy, S. Oral Manifestations and Complications of Diabetes
497 Mellitus: A review. *Sultan Qaboos University Medical Journal* **2011**, *11*(2), 179-186.
- 498 36. Herzberg, M.C. and Weyer, M.W. Dental plaque, platelets, and cardiovascular diseases. *Ann. Periodontol.*
499 **1998**, *3*, 151-160.
- 500 37. Herzberg, M.C. and Meyer, M.W. 1996. Effects of oral flora on platelets: possible consequences in
501 cardiovascular disease. *J. Periodontol.* **1996**, *67*, 1138-1142.
- 502 38. Kholy, K.E.; Genco, R.J. and Van Dyke, T.E. Oral infections and cardiovascular disease. *Trends Endocrinol*
503 *Metab.* **2015**, *26*(6), 315-21, DOI: 10.1016/j.tem.2015.03.001.
- 504 39. Guthmiller JM, Novak KF. Periodontal Diseases. In *Polymicrobial Diseases*, Brogden, K.A., Guthmiller, J.M.,
505 editors; ASM Press: Washington (DC), US, 2002. Chapter 8.
- 506 40. Wade, W.G. The oral microbiome in health and disease. *Pharmacol Res.* **2013**, *69*(1), 137-43, DOI:
507 10.1016/j.phrs.2012.11.006.
- 508 41. Abusleme, L.; Dupuy, A.K.; Dutzan, N.; Silva, N.; Burleson, J.A.; Strausbaugh, L.D.; Gamonal, J. and Diaz,
509 P.I. The subgingival microbiome in health and periodontitis and its relationship with community biomass
510 and inflammation. *ISME J.* **2013**, *7*, 1016-25, DOI: 10.1038/ismej.2012.174.
- 511 42. Pihlstrom, B.L.; Michalowicz, B.S. and Johnson, N.W. Periodontal diseases. *Lancet.* **2005**, *366*, 1809 - 1820,
512 DOI: 10.1016/S0140-6736(05)67728-8.
- 513 43. Schlafer, S.; Riep, B.; Griffen, A.L.; Petrich, A.; Hübner, J.; Berning, M.; Friedmann, A.; Göbel, U.B. and
514 Moter, A. *Filifactor alocis* - involvement in periodontal biofilms. *BMC Microbiol.* **2010**, *10*, 66.
- 515 44. Ruben, M. P. Periodontosis - an analysis and clarification of its status as a disease entity. *J. Periodontol.* **1979**,
516 *50*, 311-315.
- 517 45. Baer, P. N. The case for periodontosis as a clinical entity. *J. Periodontol.* **1971**, *42*, 516-520.
- 518 46. Manjunath, B.C.; Praveen, K.; Chandrashekar, B.R.; Rani, R.M. and Bhalla, A. Periodontal infections: a risk
519 factor for various systemic diseases. *Natl Med J India.* **2011**, *24*, 214-219.
- 520 47. American Academy of Periodontology. Position paper. Periodontal disease as a potential risk factor for
521 systemic diseases. *J. Periodontol.* **1998**, *69*, 841-850.
- 522 48. Huttenhower, C.; et al. Structure, function and diversity of the healthy human microbiome. *Nature* **2012**,
523 *486*, 207-214, DOI: 10.1038/nature11234.
- 524 49. Shaddox, L.M.; Huang, H.; Lin, T.; Hou, W.; Harrison, P.L.; Aukhil, I.; Walker, C.B.; Klepac-Ceraj, V. and
525 Paster, B.J. Microbiological Characterization in Children with Aggressive Periodontitis. *J. Dent. Res.* **2012**,
526 *91*, 927-933, DOI:10.1177/0022034512456039.

- 527 50. Jenkinson, H.F. and Lamont, R.J. Oral microbial communities in sickness and in health. *Trends Microbiol.*
528 **2005**, *13*, 589–595.
- 529 51. Kolenbrander, P. E.; Palmer, R.J.Jr.; Rickard, A.H.; Jakubovics, N.S.; Chalmers, N.I. and Diaz, P.I. Bacterial
530 interactions and successions during plaque development. *Periodontol.* **2000** **2006**, *42*, 47–79, DOI:
531 10.1111/j.1600-0757.2006.00187.x
- 532 52. Paster, B.J.; Boches, S.K.; Galvin, J.L.; Ericson, R.E.; Lau, C.N.; Levanos, V.A.; Sahasrabudhe, A. and
533 Dewhirst, F.E. Bacterial Diversity in Human Subgingival Plaque Bacterial Diversity in Human Subgingival
534 Plaque. *J. Bacteriol.* **2001**, *183*, 3770–3783, DOI: 10.1128/JB.183.12.3770-3783.2001.
- 535 53. Aruni, A.W.; Chioma, O. and Fletcher, H.M. *Filifactor alocis*: The Newly Discovered Kid on the Block with
536 Special Talents. *J Dent Res.* **2014**, *93*(8), 725 – 732.
- 537 54. Cato, E.P.; Moore L.V.H. and Moore W.E.C. *Fusobacterium alocis* sp. nov. and *Fusobacterium sulci* sp. nov.
538 from the human gingival sulcus. *Int. J. Syst. Bacteriol.* **1985**, *35*, 475-477, DOI: 10.1099/00207713-35-4-475.
- 539 55. Feuille, F.; Ebersole, J.L.; Kesavalu, L.; Stepfen, M.J. and Holt, S.C. Mixed infection with *Porphyromonas*
540 *gingivalis* and *Fusobacterium nucleatum* in a murine lesion model: potential synergistic effects on virulence.
541 *Infect Immun.* **1996**, *64*, 2094-2100.
- 542 56. Gomes, B.P.; Jacinto, R.C.; Pinheiro, E.T.; Sousa, E.L.; Zaia, A.A.; Ferraz, C.C. and Souza-Filho, F.J.
543 Molecular analysis of *Filifactor alocis*, *Tannerella forsythia* and *Treponema denticola* associated with primary
544 endodontic infections and failed endodontic treatment. *J Endod* **2006**, *32*, 937-940, DOI:
545 10.1016/j.joen.2006.05.003.
- 546 57. Sakamoto, M.; Rocas, I.N.; Siqueira, J.F.Jr. and Benno, Y. Molecular analysis of bacteria in asymptomatic
547 and symptomatic endodontic infections. *Oral Microbiol Immunol.* **2006**, *21*, 112-22.
- 548 58. Siqueira, J.F.Jr.; Rocas, I.N.; Alves, F.R.F. and Silva, M.G. Bacteria in the apical root canal of teeth with
549 primary apical periodontitis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **2009**, *107*, 721-726.
- 550 59. Fine, J.B.; Harper, D.S.; Gordon, J.M.; Hovliaras, C.A. and Charles, C.H. Short-term microbiological and
551 clinical effects of subgingival irrigation with an antimicrobial mouthrinse. *J Periodontol* **1994**, *65*, 30-6.
- 552 60. Griffen, A.L.; Beall, C.J.; Campbell, J.H.; Firestone, N.D.; Kumar, P.S.; Yang, Z.K.; Podar, M. and Leys, E.J.
553 2012. Distinct and complex bacterial profiles in human periodontitis and health revealed by 16S
554 pyrosequencing. *ISME J* **2012**, *6*, 1176-1185.
- 555 61. Kumar, P.S.; Griffen, A.L.; Barton, J.A.; Paster, B.J.; Moeschberger, M.L. and Leys, E.J. New bacterial species
556 associated with chronic periodontitis. *J Dent Res.* **2003**, *82*, 338-344.
- 557 62. Kumar, P.S.; Leys, E.J.; Bryk, J.M.; Martinez, F.J.; Moeschberger, M.L. and Griffen, A.L. Changes in
558 periodontal health status are associated with bacterial community shifts as assessed by quantitative 16S
559 cloning and sequencing. *J Clin Microbiol.* **2006**, *44*, 3665-3673, DOI: 10.1128/JCM.00317-06.
- 560 63. Aruni, A.W.; Roy, F. and Fletcher, H.M. *Filifactor alocis* has virulence attributes that can enhance its
561 persistence under oxidative stress conditions and mediate invasion of epithelial cells by *Porphyromonas*
562 *gingivalis*. *Infect Immun* **2011**, *79*, 3872-3886.
- 563 64. Wang, Q.; Jotwani, R.; Le, J.; Krauss, J.L.; Potempa, J.; Coventry, S.C.; Uriarte, S.M. and Lamont, R.J. *Filifactor*
564 *alocis* infection and inflammatory responses in the mouse subcutaneous chamber model. *Infect Immun* **2014**,
565 *82*, 1205-1212
- 566 65. Chen, H.; Liu, Y.; Zhang, M.; Wang, G.; Qi, Z.; Bridgewater, L.; Zhao, L.; Tang, Z. and Pang, X. A *Filifactor*
567 *alocis*-centered co-occurrence group associates with periodontitis across different oral habitats. *Sci Rep* **2015**,
568 *5*, 9053.
- 569 66. Wade, W.G. Has the use of molecular methods for the characterization of the human oral microbiome
570 changed our understanding of the role of bacteria in the pathogenesis of periodontal disease? *J Clin*
571 *Periodontol.* **2011**, *38*(Suppl 11), 7-16, DOI: 10.1111/j.1600-051X.2010.01679.x.
- 572 67. Moffatt, C.E.; Whitmore, S.E.; Griffen, A.L.; Leys, E.J. and Lamont, R.J. *Filifactor alocis* interactions with
573 gingivalis epithelial cells. *Mol Oral Microbiol* **2011**, *26*, 365-373.
- 574 68. Aruni, A.W.; Roy, F.; Sandberg, L. and Fletcher, H.M. Proteome variation among *Filifactor alocis* strains.
575 *Proteomics* **2012**, *12*, 3343–3364.
- 576 69. Aruni, A.W.; Chioma, O. and Fletcher, H.M. Role of Arginine deiminase in the virulence and pathogenesis
577 of *Filifactor alocis*. Proceedings of the 114th General Meeting of the American Society for Microbiology;
578 American Society for Microbiology; Abstract No: D-1621; D-1621. 2014.

- 579 70. Jalava, J and Eerola, E. Phylogenetic analysis of *Fusobacterium alocis* and *Fusobacterium sulci* based on 16S
580 rRNA gene sequences: proposal of *Filifactor alocis* (Cato, Moore and Moore) comb. nov. and *Eubacterium*
581 *sulci* (Cato, Moore and Moore) comb. nov. *Int J Syst Bacteriol*, **1999**, 49(Pt 4):1375-1379.
- 582 71. Wang, Q.; Wright, C.J.; Dingming, H.; Uriarte, S.M. and Lamont, R.J. Oral community interactions of
583 *Filifactor alocis* in vitro. *PLoS One* **2013**, 8, e76271, DOI: 10.1371/journal.pone.0076271.
- 584 72. Nath, S.G. and Raveendran, R. Microbial dysbiosis in periodontitis. *J Indian Soc Periodontol.* **2013**, 17(4), 543–
585 545, DOI: 10.4103/0972-124X.118334.
- 586 73. Kilian, M.; Chapple, I.L.C.; Hannig, M.; Marsh, P.D.; Meuric, V.; Pedersen, A.M.L.; Tonetti, M.S.; Wade,
587 W.G. and Zaura, E. The oral microbiome – an update for oral healthcare professionals. *British Dental Journal*
588 **2016**, 221, 657-666, DOI: 10.1038/sj.bdj.2016.865.
- 589 74. Marsh, P.D.; Head, D.A. and Devine, D.A. Prospects of oral disease control in the future – an opinion. *J*
590 *Oral Microbiol.* **2014**, 6, 26176.
- 591 75. Wu, J.; Peters, B.A.; Dominianni, C.; Zhang, Y.; Pei, Z.; Yang, L.; Ma, Y.; Purdue, M.P.; Jacobs, E.J.; Gapstur,
592 S.M.; Li, H.; Alekseyenko, A.V.; Hayes, R.B. and Ahn, J. Cigarette smoking and the oral microbiome in a
593 large study of American adults. *ISME J* **2016**, 10, 2435-2446.
- 594 76. Marsh, P. D.; Moter, A. and Devine, D. A. Dental plaque biofilms: communities, conflict and control.
595 *Periodontology 2000*, **2011**, 55, 16–35, DOI:10.1111/j.1600-0757.2009.00339.x.
- 596 77. Marsh, P. D.; Head, D.A. and Devine, D.A. Ecological approaches to oral biofilms: control without killing.
597 *Caries Res* **2015**, 49 (Suppl 1), 46–54.
- 598 78. Marcotte, H. and Lavoie, M.C. Oral microbial ecology and the role of salivary immunoglobulin A. *Microbiol*
599 *Mol Biol Rev* **1998**, 62, 71–109.
- 600 79. Sima, C. and Glogauer, M. Neutrophil dysfunction and host susceptibility to periodontal inflammation:
601 Current state of knowledge. *Curr Oral Health Rep.* **2014**, 1, 95–103.
- 602 80. Nussbaum, G. and Shapira, L. How has neutrophil research improved our understanding of periodontal
603 pathogenesis? *J Clin Periodontol.* **2011**, 38, 49–59.
- 604 81. Yilmaz, O. The chronicles of *Porphyromonas gingivalis*: the microbium, the human oral epithelium and their
605 interplay. *Microbiology.* **2008**, 154, 2897–2903.
- 606 82. Darveau, R.P. *Porphyromonas gingivalis* neutrophil manipulation: risk factor for periodontitis? *Trends*
607 *Microbiol.* **2014**, 22(8), 428-429.
- 608 83. Hajishengallis, G. Periodontitis: from microbial immune subversion to systemic inflammation. *Nat Rev*
609 *Immunol.* **2015**, 15(1), 30–44, DOI:10.1038/nri3785.
- 610 84. Olsen, I. and Hajishengallis, G. Major neutrophil functions subverted by *Porphyromonas gingivalis*. *J Oral*
611 *Microbiol.* **2016**, 8, 30936.
- 612 85. Brigham, C.; Caughlan, R.; Gallegos, R.; Dallas, M.B.; Godoy, V.G. and Malamy, M.H. Sialic acid (N-acetyl
613 neuraminic acid) utilization by *Bacteroides fragilis* requires a novel N-acetyl mannosamine epimerase. *J.*
614 *Bacteriol.* **2009**, 191, 3629–3638, DOI:10.1128/JB.00811-08.
- 615 86. Lamont, R. J.; Meila, M.; Xia, Q. and Hackett, M. Mass spectrometry-based proteomics and its application
616 to studies of *Porphyromonas gingivalis* invasion and pathogenicity. *Infect. Disord. Drug Targets* **2006**, 6, 311–
617 25.
- 618 87. Al-Haroni, M.; Skaug, N.; Bakken, V. and Cash, P. Proteomic analysis of ampicillin-resistant oral
619 *Fusobacterium nucleatum*. *Oral Microbiol. Immunol.* 2008, 23, 36–42.
- 620 88. Casiano-Colon, A. and Marquis, R. E. Role of the arginine deiminase system in protecting oral bacteria and
621 an enzymatic basis for acid tolerance. *Appl. Environ. Microbiol.* 1988, 54, 1318–1324.
- 622 89. Cunin, R.; Glansdorff, N.; Piérard, A. and Stalon, V. Biosynthesis and metabolism of arginine in bacteria.
623 *Microbiol. Rev.* 1986, 50, 314–352.
- 624 90. Aruni, W., E. Vanterpool, D. Osbourne, F. Roy, A. Muthiah, Y. Dou, and H. M. Fletcher. Sialidase and
625 sialoglycoproteases can modulate virulence in *Porphyromonas gingivalis*. *Infect.Immun.* **2011**, 79, 2779-2791.
- 626 91. Hernichel-Gorbach, E.; Kornman, K.S.; Holt, S.C.; Nichols, F.; Meador, H.; Kung, J.T. and Thomas, C.A.
627 Host responses in patients with generalized refractory periodontitis. *J Periodontol.* **1994**, 65, 8–16.
- 628 92. Offenbacher, S.; Collins, J.G.; Yalta, B. and Haradon, G. Role of prostaglandins in high-risk periodontitis
629 patients. In: *Molecular pathogenesis of periodontal disease.* Genco R.; Hamada, S.; Lehner, T.; McGhee, J.;
630 Mergenhagen, S., editors; American Society for Microbiology : Washington, D.C. US, 1994; pp. 203–214.
- 631 93. Romero, R.; Baumann, P.; Gomez, R.; Salafia, C.; Rittenhouse, L.; Barberio, D.; Behnke, E.; Cotton, D.B. and
632 Mitchell, M.D. The relationship between spontaneous rupture of membranes, labor, and microbial invasion

- 633 of the amniotic cavity and amniotic fluid concentrations of prostaglandins and thromboxane B2 in term
634 pregnancy. *Am J Obstet Gynecol.* **1993**, *168*, 1654–1664.
- 635 94. Kleindienst, R.; Xu, Q.; Willeit, J.; Waldenberger, F.R.; Weimann, S. and Wick, G. Immunology of
636 atherosclerosis: demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta
637 or gamma/delta receptor in human atherosclerotic lesions. *Am J Pathol.* **1993**, *142*, 1927–1937.
- 638 95. Loesche, W.J. and Lopatin, D.E. Interactions between periodontal disease, medical diseases and immunity
639 in the older individual. *Periodontol 2000.* **1998**, *16*, 80–105.
- 640 96. Oz, H.S. and Puleo, D.A. “Animal Models for Periodontal Disease”, *Journal of Biomedicine and Biotechnology*,
641 vol. 2011, Article ID 754857, 8 pages, **2011**. doi:10.1155/2011/754857
- 642 97. Schou, S.; Holmstrup, P. and Kornman, K.S. “Non-human primates used in studies of periodontal disease
643 pathogenesis: a review of the literature,” *Journal of Periodontology*, 1993, vol. 64, no. 6, pp. 497–508.
- 644 98. Wang, S.; Liu, Y.; Fang, D. and Shi, S. The miniature pig: a useful large animal model for dental and
645 orofacial research. *Oral Diseases*, **2007**, vol. 13, no. 6, pp. 530–537, 2007.
- 646 99. Kesavalu, L.; Ebersole, J.L.; Machen, R.L. and Holt, S.C. *Porphyromonas gingivalis*-virulence in mice:
647 induction of immunity to bacterial components. *Infection and Immunity*, **1992**, vol. 60, no. 4, pp. 1455–1464.